GlassScriptPhysician profile
Gregory A Kozeny
NPI 1861499550
$2,644.04
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $805 · 2020: $227 · 2021: $379 · 2022: $406 · 2023: $757 · 2024: $69.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $943.39 | 2019-2024 | Veltassa |
| Amgen INC. | $360.50 | 2019-2023 | Tavneos, Aranesp, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $273.19 | 2019-2023 | Farxiga, Evusheld, Lokelma |
| Travere Therapeutics, INC. | $143.12 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $139.30 | 2019-2023 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $135.76 | 2019-2023 | Jynarque |
| Akebia Therapeutics INC | $106.00 | 2019-2023 | Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $84.02 | 2022-2023 | |
| Horizon Therapeutics Plc | $79.29 | 2019-2023 | Krystexxa |
| Pfizer INC. | $62.72 | 2019 | |
| Daiichi Sankyo INC. | $61.02 | 2019 | |
| Mallinckrodt Enterprises LLC | $45.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.56 | 2022-2023 | Gattex |
| Fresenius USA Marketing, INC. | $34.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.12 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $24.04 | 2020 | |
| Calliditas Therapeutics US INC. | $23.48 | 2022 | |
| Lundbeck LLC | $21.42 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.63 | 2019 | |
| Glaxosmithkline, LLC. | $14.96 | 2023 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Kozeny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.